Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings

Annals of Diagnostic Pathology

Volumn 13, Issue 3, 2009, Pages 151-157

  Alvarado Cabrero, Isabel ^a   Alderete Vázquez, Georgia ^a   Quintal Ramírez, Marissa ^a   Patiño, Marcia ^b   Ruíz, Erika ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b Department of Pathology   (Ecuador)

Author keywords

Locally advanced breast cancer; Neoadjuvant chemotherapy; Pathologic response

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; COHORT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67349236094     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2009.02.003     Document Type: Article

References (30)

1. Pusztai L. Preoperative systemic chemotherapy and pathologic assessment of response. Pathol Oncol Res 14 (2008) 169-171
2. Cleator S., Parton M., and Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer 9 (2002) 183-195
3. Bonaddona G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52 (1992) 2127-2137
4. Fisher B., Gunduz N., Coyle J., Rudock C., and Saffer E.A. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 49 (1989) 1996-2001
5. Newman L.A., Pernick N.L., Adsay V., et al. Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome. Ann Surg Oncol 10 (2003) 734-739
6. Gonzalez-Angulo A., McGuire S., Buchholz T.A., et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23 (2005) 7098-7104
7. Charfare H., Limongelli S., and Purushotham A.D. Neoadjuvant chemotherapy in breast cancer. Br J Surg 92 (2005) 14-23
8. Bonadonna G., Veronesi U., Brambilla C., and Ferrari L. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82 (1990) 1539-1545
9. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy in local-regional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
10. Jacquillat C.I., Weil M., Aucler G., et al. Neoadjuvant chemotherapy in the conservative management of breast cancers: study of 143 patients. Recent Results Cancer Res 103 (1986) 113-119
11. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
12. Jones R.L., Lakhani S.R., Ring A.E., et al. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 94 (2006) 358-362
13. Chevallier B., Roche H., Olivier J.P., et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16 (1993) 223-228
14. Portera C.C., and Swain S.M. Neoadjuvant chemotherapy: a step closer to individualized therapy. In: Govindan R. (Ed). ASCO educational book (2007), ASCO, Alexandria (Va) 51-55
15. Rajan R., Poniecka A., Smith T.L., et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100 (2004) 1365-1373
16. Fisher E.R., Wang J., Bryant J., Fisher B., Mamounas E., and Wolmark N. Pathobiology of preoperative chemotherapy. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18. Cancer 95 (2002) 681-695
17. Apple S.K., and Suthar F. How do we measure a residual tumor size in histopathology (the gold standard) after neoadjuvant chemotherapy?. Breast 15 (2006) 370-376
18. Kaufmann M., von Minckwitz G., and Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 14 (2005) 576-581
19. Cristofanilli M., Gonzalez-Angulo A., Sniege N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23 (2005) 41-48
20. Colleoni M., Minchella I., Mazzarol G., et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11 (2000) 1057-1059
21. Buzdar A.U., Valero V., Theriault R.L., et al. Pathologic complete response to chemotherapy is related with hormone receptor status. Breast Cancer Res Treat 82 (2003) S69a
22. Teixeira C., Reed J.C., and Pratt M.A. Estrogen promotes chemotherapeutic drug resistance by mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55 (1995) 3902-3907
23. Rasbridge S.A., Gillett C.E., Seymour A.M., et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70 (1994) 335-341
24. Feldman L.D., Hortobagyi G.N., Buzdar A.U., et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46 (1986) 2578-2581
25. Morrow M., Bravermon A., Thelmo W., et al. Multimodal therapy for locally advanced breast cancer. Arch Surg 121 (1986) 1291-1296
26. Newman L.A., Buzdar A.U., and Singletary S.E. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast conservation therapy feasibility. Ann Surg Oncol 9 (2002) 228-234
27. Singh M., Capocelli K.E., Marks J.L., et al. Expression of vascular endothelial growth factor and proliferation marker MiB1 are influenced by neoadjuvant chemotherapy in locally advanced breast cancer. Appl Immunohistochem Mol Morphol 13 (2005) 147-156
28. Klauber-DeMore N., Ollila D.W., Moore D.T., et al. Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic. Ann Surg Oncol 13 (2006) 685-691
29. Lenert J.T., Vlastos G., and Mirza N.Q. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 6 (1999) 762-767
30. Pu R.T., Schott A.F., Sturtz D.E., et al. Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy. Am J Surg Pathol 29 (2005) 354-358